PapersFlow Research Brief
Diabetes Management and Research
Research Guide
What is Diabetes Management and Research?
Diabetes management and research is the clinical and scientific work of diagnosing diabetes, monitoring glycemia and complications, and evaluating interventions to reduce hyperglycemia and diabetes-related morbidity and mortality.
The provided corpus contains 112,812 works on diabetes management and research, spanning diagnostic classification, risk stratification, and interventional trials in outpatient and inpatient settings. Widely used clinical definitions and diagnostic categories are codified in "Diagnosis and Classification of Diabetes Mellitus" (2010) and "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus" (2002). Major outcomes evidence includes long-term complication reduction with intensive therapy in type 1 diabetes ("The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993)) and complication risk modification in type 2 diabetes ("Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" (1998)).
Research Sub-Topics
Homeostasis Model Assessment of Insulin Resistance
This sub-topic refines HOMA-IR and HOMA-β models using fasting glucose/insulin for β-cell function and resistance quantification. Researchers validate against clamps and apply in epidemiology.
Intensive Glycemic Control in Type 1 Diabetes
Studies outcomes of tight glucose management on microvascular/macrovascular complications from trials like DCCT. Includes insulin regimens, monitoring, and long-term legacy effects.
SGLT2 Inhibitors and Cardiovascular Outcomes
Investigates empagliflozin and class effects on heart failure, mortality, and renal endpoints in T2DM. Researchers analyze mechanisms like natriuresis and trial data.
Diabetes Diagnosis and Classification Criteria
This area updates ADA/WHO standards for HbA1c, OGTT, and fasting glucose thresholds across types. Studies address prediabetes, gestational diabetes, and epidemiological shifts.
Global Diabetes Prevalence Projections and Epidemiology
Focuses on IDF Atlas modeling of incidence, prevalence, and urbanization/obesity drivers to 2045. Researchers forecast burdens and disparities across regions.
Why It Matters
Diabetes management decisions directly affect rates of microvascular and macrovascular complications, making evidence on glycemic targets, therapies, and monitoring clinically consequential. "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993) reported that intensive therapy delayed onset and slowed progression of diabetic retinopathy, nephropathy, and neuropathy in insulin-dependent diabetes mellitus, establishing complication prevention as a central goal of day-to-day management. For type 2 diabetes patients at high cardiovascular risk, Zinman et al. (2015) in "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" found lower rates of the primary composite cardiovascular outcome and death from any cause when empagliflozin was added to standard care, linking glucose-lowering therapy choice to cardiovascular outcomes rather than glycemia alone. In hospital and critical care, Van den Berghe et al. (2001) in "Intensive Insulin Therapy in Critically Ill Patients" showed that targeting blood glucose at or below 110 mg per deciliter reduced morbidity and mortality in a surgical intensive care unit, illustrating that diabetes-related glycemic management extends beyond outpatient endocrinology into perioperative and ICU protocols. At the population level, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition" (2019) and "International Diabetes Federation 2017" (2018) exemplify how prevalence estimation and projection work informs health-system planning, screening priorities, and resource allocation.
Reading Guide
Where to Start
Start with "Diagnosis and Classification of Diabetes Mellitus" (2010) because it provides a high-level, widely cited definition and classification framework that anchors how studies and guidelines define diabetes and its categories.
Key Papers Explained
Matthews et al. (1985) in "Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man" provides a practical metabolic measurement approach often used to characterize insulin resistance and beta-cell function in research cohorts. "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993) connects glycemic management intensity to microvascular complication trajectories in insulin-dependent diabetes mellitus. "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" (1998) extends the complications-focused question to type 2 diabetes in a large trial context. Van den Berghe et al. (2001) in "Intensive Insulin Therapy in Critically Ill Patients" shows that glucose management strategies also apply to acute inpatient care with explicit targets (at or below 110 mg per deciliter). Zinman et al. (2015) in "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" links diabetes pharmacotherapy to cardiovascular outcomes and mortality, broadening endpoints beyond glycemia and microvascular disease.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
For population and health-system research directions, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition" (2019) and "International Diabetes Federation 2017" (2018) motivate work on forecasting burden and planning services. For clinical research frontiers, the most immediate next steps suggested by the listed trials are refining which patients benefit most from cardiovascular-outcomes-focused therapies (as in Zinman et al. (2015)) and determining how intensive glycemic strategies should be implemented safely across settings, including critical care (as in Van den Berghe et al. (2001)).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Homeostasis model assessment: insulin resistance and ?-cell fu... | 1985 | Diabetologia | 30.9K | ✓ |
| 2 | The Effect of Intensive Treatment of Diabetes on the Developme... | 1993 | New England Journal of... | 24.5K | ✓ |
| 3 | Intensive blood-glucose control with sulphonylureas or insulin... | 1998 | The Lancet | 19.9K | ✕ |
| 4 | Diagnosis and Classification of Diabetes Mellitus | 2010 | Diabetes Care | 14.0K | ✓ |
| 5 | International Diabetes Federation 2017 | 2018 | Journal of Diabetes | 13.5K | ✓ |
| 6 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type ... | 2015 | New England Journal of... | 11.5K | ✓ |
| 7 | Report of the Expert Committee on the Diagnosis and Classifica... | 2002 | Diabetes Care | 10.4K | ✕ |
| 8 | Intensive Insulin Therapy in Critically Ill Patients | 2001 | New England Journal of... | 9.9K | ✓ |
| 9 | Global and regional diabetes prevalence estimates for 2019 and... | 2019 | Diabetes Research and ... | 9.9K | ✕ |
| 10 | Standards of Medical Care in Diabetes | 2006 | Diabetes Care | 8.7K | ✓ |
In the News
Breakthrough T1D Awards $1.5 Million Grant to Blue Circle ...
NEW YORK,Jan. 15, 2026/PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced a $1.5 million, three-year grant to Blue Circle ...
Reprogramming immunity to rewrite the story of Type 1 ...
With Breakthrough T1D funding, an MUSC researcher will study therapeutic options that address the underlying causes of type 1 diabetes. By Sophia Barry Gordon January 07, 2026 * Share * * *
Type 1 Diabetes Funding Opportunities
A comprehensive collection of Breakthrough T1D’s grant mechanisms and descriptions; application guidelines and checklists; administrative resources; terms and conditions (updated July 2025); clinic...
UB pharmacy researcher makes diabetes breakthrough in ...
Diabetes and Digestive and Kidney Diseases.
Current Funding Opportunities—Primary Care RFA (2026)
This call for applications aims to attract outstanding researchers interested in improving diabetes care within the primary health care setting. The ADA seeks to support studies that will develop, ...
Code & Tools
| | | View all files | ## Repository files navigation # 🩸Diabetic Utils Built and maintained by Mark Learst. **The professional TypeScript toolk...
Hello! Welcome to the repository for Diabetica . Our study introduced a reproducible framework for developing a specialized LLM capable of handlin...
The study in this repositoy aims to implement the QOF diabetes indicators in OpenSAFELY using ehrQL (Electronic Health Record Query Language) . ## ...
**Flask** is a web framework for building web applications using the Python programming language. It is a micro-framework that provides the basic f...
This Github organisation contains a number of repositories from members of the Exeter Diabetes research team and collaborators. Many are linked to ...
Recent Preprints
BMJ Open Diabetes Research & Care: Homepage
BMJ Open Diabetes Research & Care is an open access journal committed to publishing high-quality basic and clinical research articles regarding type 1 and type 2 diabetes and associated complicatio...
Diabetes Care
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) celebrates 75 years of advancing health. A new collection in*Diabetes Care*and*Diabetes*highlights landmark research and...
Journal of Diabetes Research
_Journal of Diabetes Research_ publishes articles related to type 1 and type 2 diabetes. Topics include etiology, pathogenesis, management, and prevention of diabetes, as well as associated complic...
JMIR Diabetes
*JMIR Diabetes*(JD, ISSN 2371-4379) focuses on technologies, medical devices, apps, engineering, informatics and patient education for diabetes prevention, self-management, care, and cure, to help ...
Diabetes
JAMA Pediatrics (122) JAMA Surgery (98) JAMA Dermatology (73) JAMA Neurology (73) JAMA Cardiology (56) JAMA Psychiatry (42) JN Learning (35) JAMA Otolaryngology–Head & Neck Surgery (13) JAM...
Latest Developments
Recent developments in diabetes management and research as of February 2026 include advances in technology such as real-time continuous glucose monitoring recommended by the ADA Standards of Care, and the potential approval of a continuous ketone monitoring system; significant updates to the 2026 “Standards of Care” emphasizing evidence-based, person-centered strategies; and promising clinical trials exploring automated insulin delivery systems and new medications like Tzield for early-stage type 1 diabetes, along with ongoing research into innovative treatments and predictive AI modeling (NKC Health, diabetesjournals.org, TrialX).
Sources
Frequently Asked Questions
What is the clinical definition of diabetes mellitus used in major guidelines?
"Diagnosis and Classification of Diabetes Mellitus" (2010) defines diabetes mellitus as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The same document links chronic hyperglycemia to long-term damage, dysfunction, and failure of multiple organs.
How is insulin resistance and beta-cell function commonly estimated in clinical research?
Matthews et al. (1985) in "Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man" described estimating insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations. This approach is widely used for risk stratification and for comparing metabolic phenotypes across studies.
Why did intensive glycemic control become a central strategy in type 1 diabetes management?
"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993) reported that intensive therapy delays onset and slows progression of diabetic retinopathy, nephropathy, and neuropathy in insulin-dependent diabetes mellitus. This evidence connected routine glycemic management to prevention of long-term complications.
How did evidence from type 2 diabetes trials shape treatment goals related to complications?
"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" (1998) evaluated intensive blood-glucose control versus conventional treatment and its relationship to complication risk in type 2 diabetes. The trial is frequently cited in discussions of how glucose-lowering intensity relates to downstream complication outcomes.
Which therapies have been shown to improve cardiovascular outcomes in type 2 diabetes in a major outcomes trial?
Zinman et al. (2015) in "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" reported lower rates of the primary composite cardiovascular outcome and death from any cause with empagliflozin compared with placebo when added to standard care in high-risk type 2 diabetes patients. This positioned cardiovascular outcomes as a key endpoint for therapy selection.
How is tight glucose control used in critical care settings, and what target was studied?
Van den Berghe et al. (2001) in "Intensive Insulin Therapy in Critically Ill Patients" studied intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter in a surgical intensive care unit. The study reported reduced morbidity and mortality under that approach in the studied setting.
Open Research Questions
- ? How should outpatient glycemic targets be individualized to balance complication prevention shown in "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993) with differing risks and contexts not specified in that trial abstract?
- ? Which patient subgroups with type 2 diabetes derive the greatest cardiovascular and mortality benefit from adding empagliflozin, beyond the high cardiovascular-risk population described in "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes" (2015)?
- ? What are the optimal ICU glucose targets and implementation strategies to reproduce the morbidity and mortality reductions reported in "Intensive Insulin Therapy in Critically Ill Patients" (2001) across different critical care populations?
- ? How can fasting-based indices from "Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man" (1985) be best integrated with modern diagnostic classifications in "Diagnosis and Classification of Diabetes Mellitus" (2010) for prediction of complications and treatment response?
- ? How should prevalence projections from "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition" (2019) be translated into screening and prevention policies consistent with classification frameworks in "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus" (2002)?
Recent Trends
Within the provided evidence set, highly cited work spans foundational measurement (Matthews et al. "Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man"), complication-prevention trials ("The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus" (1993); "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" (1998)), and broader outcomes and settings (Van den Berghe et al. (2001) ICU glycemic targets at or below 110 mg per deciliter; Zinman et al. (2015) cardiovascular outcomes and mortality).
1985Population burden estimation and projection are represented by Saeedi et al. in "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition" and by "International Diabetes Federation 2017" (2018).
2019The topic’s scale in the provided dataset is large (112,812 works), consistent with sustained research activity across diagnosis, treatment, complications, and epidemiology, although a 5-year growth rate is not provided.
Research Diabetes Management and Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Diabetes Management and Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.